166 related articles for article (PubMed ID: 2939948)
1. Splenocytes from tumor-bearing Corynebacterium parvum treated mice maintain interleukin-2 and -3 activity.
Roberson AM; Elgert KD
Cancer Immunol Immunother; 1986; 22(1):49-55. PubMed ID: 2939948
[TBL] [Abstract][Full Text] [Related]
2. Mechanism for macrophage activation against Corynebacterium parvum--participation of T cells and its lymphokines.
Mori H; Mihara M; Uesugi Y; Nagai H; Koda A
Microbiol Immunol; 1994; 38(12):983-8. PubMed ID: 7723692
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of the potentiation of specific antitumor immunity by intratumor injection of Corynebacterium parvum.
Miyata H; Himeno K; Nomoto K
Cancer Res; 1983 Oct; 43(10):4670-5. PubMed ID: 6883325
[TBL] [Abstract][Full Text] [Related]
4. In vitro antitumor effect of lymphoid cells from Corynebacterium parvum-treated mice: effect of route of C. parvum administration.
Ghaffar A; Cullen RT
J Natl Cancer Inst; 1977 Mar; 58(3):717-20. PubMed ID: 300113
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 2 (IL-2) activity during tumor growth: IL-2 production kinetics, absorption of and responses to exogenous IL-2.
Burger CJ; Elgert KD; Farrar WL
Cell Immunol; 1984 Apr; 84(2):228-39. PubMed ID: 6231106
[TBL] [Abstract][Full Text] [Related]
6. Modulation of suppressor mechanism in allergic contact dermatitis. IV. Selective inhibition of suppressor T-lymphocytes by serum obtained from Corynebacterium parvum treated mice.
Knop J; Riechmann R; Macher E
J Invest Dermatol; 1981 Dec; 77(6):469-73. PubMed ID: 6458637
[TBL] [Abstract][Full Text] [Related]
7. Antitumor antibodies and immunoglobulin class and subclass levels in Corynebacterium parvum-treated mice.
James K; Willmott N; Milne I; McBride WH
J Natl Cancer Inst; 1976 May; 56(5):1035-40. PubMed ID: 825650
[TBL] [Abstract][Full Text] [Related]
8. Effects of different fractions of Corynebacterium parvum on the cytotoxic T-cell response to alloantigens in mice.
Lichtenstein A; Tuttle R; Cantrell J; Zighelboim J
J Natl Cancer Inst; 1982 Aug; 69(2):495-501. PubMed ID: 6213807
[TBL] [Abstract][Full Text] [Related]
9. Effect of 1,1-dimethylhydrazine (UDMH) on Corynebacterium parvum-associated immunosuppression in mice.
Frazier DE; Bauer RM; Tarr MJ; Olsen RG
Int J Immunopharmacol; 1992 Jan; 14(1):27-34. PubMed ID: 1316318
[TBL] [Abstract][Full Text] [Related]
10. Immunopotentiation of cell-mediated hypersensitivity by Corynebacterium parvum (Propionibacterium acnes).
Maguire HC; Cipriano D
Int Arch Allergy Appl Immunol; 1983; 70(1):34-9. PubMed ID: 6848475
[TBL] [Abstract][Full Text] [Related]
11. Possible mechanisms in the anti-tumour activity of C. parvum.
Cullen RT
Dev Biol Stand; 1977 Apr 13-15; 38():265-71. PubMed ID: 305375
[TBL] [Abstract][Full Text] [Related]
12. Effect of Corynebacterium parvum on tumor growth in normal and athymic (nude) mice.
Woodruff MF; Warner NL
J Natl Cancer Inst; 1977 Jan; 58(1):111-6. PubMed ID: 299893
[TBL] [Abstract][Full Text] [Related]
13. Mchanisms of antitumor action of Corynebacterium parvum: nonspecific tumor cell destruction at site of immunologically mediated sensitivity reaction to C. parvum.
Tuttle RL; North RJ
J Natl Cancer Inst; 1975 Dec; 55(6):1403-11. PubMed ID: 1206760
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of IL-2 and Corynebacterium parvum following direct intracranial injection.
Sutton RC; Kennedy J; Duncan J; Conley FK
J Neurooncol; 1989 Sep; 7(3):261-7. PubMed ID: 2795120
[TBL] [Abstract][Full Text] [Related]
15. Decreased resistance to Listeria monocytogenes in mice injected with killed corynebacterium parvum: association with suppression of cell-mediated immunity.
Wing EJ; Kresefsky-Friedman DY
J Infect Dis; 1980 Feb; 141(2):203-11. PubMed ID: 6767792
[TBL] [Abstract][Full Text] [Related]
16. A role for T lymphocytes in the antitumour action of systemic C. parvum.
McBride WH; Peters LJ; Mason KA; Milas L
Dev Biol Stand; 1977 Apr 13-15; 38():253-7. PubMed ID: 305374
[TBL] [Abstract][Full Text] [Related]
17. Tumour growth, phagocytic activity and antibody response in Corynebacterium parvum-treated mice.
Woodruff MF; McBride WH; Dunbar N
Clin Exp Immunol; 1974 Jul; 17(3):509-18. PubMed ID: 4549691
[TBL] [Abstract][Full Text] [Related]
18. The in vivo immunosuppressive action of suppressor cells from alloantigen-cyclosporine-treated mice and the capacity of spleen cells to release interleukins and gamma-interferon.
Yoshimura N; Matsui S; Hamashima T; Kita M; Oka T
Transplantation; 1988 Jan; 45(1):157-62. PubMed ID: 2962348
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Fc receptor expression by a sub-population of murine intra-tumour macrophages following intravenous Corynebacterium parvum therapy.
Moore K; McBride WH
Br J Cancer; 1983 Jun; 47(6):797-802. PubMed ID: 6860547
[TBL] [Abstract][Full Text] [Related]
20. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
Shu SY; Chou T; Sakai K
J Immunol; 1989 Jul; 143(2):740-8. PubMed ID: 2738408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
